[144] Legend Biotech Corporation American SEC Filing

Rhea-AI Filing Summary

Legend Biotech Corp. (LEGN) filed a Form 144 indicating the proposed sale of 642 American Depositary Shares (ADS)—acquired through restricted-stock vesting on 03/20/2025 and valued at roughly $28,890—through Fidelity Brokerage Services. The seller plans to execute the trade on or about 07/23/2025 on NASDAQ. No other sales have occurred in the past three months, and the filing states that 367.3 million shares are outstanding.

The notice is routine: it simply pre-clears a small disposition under SEC Rule 144. The stake represents 0.00017% of shares outstanding, signalling no material change to ownership structure or to the investment thesis. The seller attests to having no undisclosed adverse information and, if relying on Rule 10b5-1, certifies plan adoption.

Insights

Securities Analyst

TL;DR Tiny insider sale (642 ADS, $29k) is immaterial to LEGN’s float; neutral market impact.

The Form 144 merely signals intent, not certainty, of sale. With 367 million shares outstanding, the proposed divestiture is negligible. No pattern of ongoing selling is disclosed, and the shares stem from normal compensation vesting. Investors should not expect liquidity or valuation effects. Monitoring larger-scale insider activity or substantive corporate events remains more relevant for the LEGN thesis.

Corporate Governance Expert

TL;DR Routine Rule 144 filing shows compliance; no governance red flags.

The filer follows Rule 144 disclosure requirements and affirms absence of undisclosed MNPI. Because the transaction size is de minimis, there is no concern about control changes or signaling of insider pessimism. Continued transparency in future filings sustains good governance practices.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	642	28890.00	367298315	07/23/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	03/20/2025	Restricted Stock Vesting	Issuer			642	03/20/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Legend Biotech (LEGN) shares are being sold under this Form 144?

The filing covers 642 American Depositary Shares.

What is the estimated value of the proposed LEGN share sale?

The aggregate market value is approximately $28,890.

When is the planned sale date for the LEGN shares?

The filer lists an approximate sale date of 07/23/2025.

What percentage of Legend Biotech’s outstanding shares does the sale represent?

About 0.00017% of the stated 367,298,315 shares outstanding.

Were any other LEGN shares sold by this insider in the past three months?

No. The filer reported "Nothing to Report" for prior three-month sales.